0.0015% tafluprost

DRUG2 trials

Sponsors

Santen Inc., Gangnam Severance Hospital

Conditions

Glaucoma and Ocular HypertensionPrimary Open-angle Glaucoma

Phase 1

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

CompletedNCT01654484

Santen Inc.Glaucoma and Ocular Hypertension

Start: 2012-07-31End: 2012-11-30Updated: 2018-04-18

Phase 4

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

CompletedNCT03104621

Gangnam Severance HospitalPrimary Open-angle Glaucoma

Start: 2013-03-31End: 2015-09-30Updated: 2017-04-07